144 related articles for article (PubMed ID: 26872140)
1. Development of Antibiotic Resistance during Simulated Treatment of Pseudomonas aeruginosa in Chemostats.
Feng Y; Hodiamont CJ; van Hest RM; Brul S; Schultsz C; Ter Kuile BH
PLoS One; 2016; 11(2):e0149310. PubMed ID: 26872140
[TBL] [Abstract][Full Text] [Related]
2. Optimization of therapy against Pseudomonas aeruginosa with ceftazidime and meropenem using chemostats as model for infections.
Feng Y; Bakker RT; van Hest RM; Hodiamont CJ; Brul S; Schultsz C; Ter Kuile BH
FEMS Microbiol Lett; 2017 Aug; 364(14):. PubMed ID: 28854670
[TBL] [Abstract][Full Text] [Related]
3. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa.
Oie S; Sawa A; Kamiya A; Mizuno H
J Antimicrob Chemother; 1999 Nov; 44(5):689-91. PubMed ID: 10552987
[TBL] [Abstract][Full Text] [Related]
4. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
Henrichfreise B; Wiegand I; Luhmer-Becker I; Wiedemann B
Antimicrob Agents Chemother; 2007 Oct; 51(10):3642-9. PubMed ID: 17682103
[TBL] [Abstract][Full Text] [Related]
5. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
6. In vitro effect of subinhibitory concentrations of ceftazidime and meropenem on the serum sensitivity of Pseudomonas aeruginosa strains.
Drenjancević D; Vranes J; Bedenić B; Sakić-Zdravcević K
Coll Antropol; 2007 Mar; 31(1):221-5. PubMed ID: 17598405
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of Mutations during Development of Resistance by Pseudomonas aeruginosa against Five Antibiotics.
Feng Y; Jonker MJ; Moustakas I; Brul S; Ter Kuile BH
Antimicrob Agents Chemother; 2016 Jul; 60(7):4229-36. PubMed ID: 27139485
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
Huband MD; Castanheira M; Flamm RK; Farrell DJ; Jones RN; Sader HS
Antimicrob Agents Chemother; 2016 Apr; 60(4):2537-41. PubMed ID: 26810650
[TBL] [Abstract][Full Text] [Related]
9. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
[TBL] [Abstract][Full Text] [Related]
10.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
12. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
13. Comparison of biofilm formation and antibiotic resistance pattern of Pseudomonas aeruginosa in human and environmental isolates.
Gholami S; Tabatabaei M; Sohrabi N
Microb Pathog; 2017 Aug; 109():94-98. PubMed ID: 28549926
[TBL] [Abstract][Full Text] [Related]
14. Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.
Tam VH; Chang KT; Zhou J; Ledesma KR; Phe K; Gao S; Van Bambeke F; Sánchez-Díaz AM; Zamorano L; Oliver A; Cantón R
J Antimicrob Chemother; 2017 May; 72(5):1421-1428. PubMed ID: 28158470
[TBL] [Abstract][Full Text] [Related]
15. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
Nasu Y; Abe M; Ono N; Araki M; Horimi T; Takahashi I
Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905
[TBL] [Abstract][Full Text] [Related]
16. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
Solé M; Fàbrega A; Cobos-Trigueros N; Zamorano L; Ferrer-Navarro M; Ballesté-Delpierre C; Reustle A; Castro P; Nicolás JM; Oliver A; Martínez JA; Vila J
J Antimicrob Chemother; 2015 Nov; 70(11):3004-13. PubMed ID: 26260130
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftazidime and other beta-lactam antibiotics against nosocomial strains of Pseudomonas aeruginosa.
Santos Ferreira MO; Bacelar MJ; Canica MM
J Int Med Res; 1984; 12(6):356-60. PubMed ID: 6440822
[TBL] [Abstract][Full Text] [Related]
18. Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity.
Pournaras S; Maniati M; Spanakis N; Ikonomidis A; Tassios PT; Tsakris A; Legakis NJ; Maniatis AN
J Antimicrob Chemother; 2005 Oct; 56(4):761-4. PubMed ID: 16115825
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
[TBL] [Abstract][Full Text] [Related]
20. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
